BTKis are a mainstay in CLL treatment, with patient-specific considerations ultimately driving physicians’ choice of agent. Selection depends on AEs, comorbidities, ease of administration, prior lines of systemic therapy, drug-drug interactions, cost, and resistance profile. In patients with a histo...
Another way to improve the care is by increasing knowledge of our patients with hematologic malignancies of their disease; this might be achieved by patient's organizations. If patients don't have the right information, they won't try to access the right treatment. Therefore, it is essential ...
PH, DRH, TM, AR, DA, AB, AH and DP are responsible for the Protocol/Patient Information Sheet. DRH, JBO, LC, AH and PH wrote the manuscript. All authors read and approved the final manuscript. The trial will comply with the authorship criteria recommended by the International Committee ...
Data sheet and information supplied by the manufacturer confirm the rare occurrence of serious immune thrombocytopenia, recommending discontinuation of therapy when platelet counts fall below 50脳10 9 /l. We report a patient with refractory CLL in which relentless progressive cytopenia occurred despite ...
Patient education is often overlooked in its role in the control and prevention of high blood pressure. This paper analyzes the causes and physiology behind high blood pressure as they relate to the current nursing interventions. The role of nurses is discussed in relation to patient education ...